Dublin, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/q8ggs7/human_microbiome) has announced the addition of the "Human Microbiome Market by Indication, Application, Product, Product Research & Technology Research - Global Forecast to 2023" report to their offering.
Existing opportunities and huge research investments by several key players in microbiome arena facilitate human microbiome market to gain market traction
The human microbiome market is an emerging market with abundant opportunities. The market is expected to flourish within five to seven years owing to a number of products currently under the clinical trial phase. The market potential is quite large, considering the structure of the market.
The factors driving this market include rising aging population, increasing incidences of lifestyle diseases, gradual demand for efficient and safe medication with no side effects, and treatment of diseases having a limited success rate. The factors restraining this market include lack of comprehensive research to assist in market pull, lack of awareness among the population regarding the efficient usage and effect of prebiotics and probiotics, and impending government regulations on probiotics and prebiotics.
The human microbiome market is divided into three major segments, namely, application, disease, and product. Different products in the market and its usage are expected to contribute to the growth of the overall market. Increase in lifestyle diseases will help the market to proliferate, while the application segment is also considered as a major driving factor for the market. Also, the human microbiome research spending market is broadly segmented by product and technology.
Europe is expected to command as a resourceful market with the largest share in the human microbiome market and expected to grow within the coming years. The primary growth driver for Europe is the aging population size and the increasing lifestyle diseases. The increasing need among the population to stay fit and have a healthy lifestyle has leveraged the use of prebiotics and probiotics. The consumers seek for a wider variety of food and beverages that contain beneficial probiotics and prebiotics and other food supplements that helps to maintain microbiome balance.
APAC accounted for the second-largest market share and will be the main focus of the market in the coming five years that will register high-growth rates for all the segments. The U.S. market at present is a niche market due to the lack of awareness among the population regarding the beneficial usage of prebiotics and probiotics. However, the U.S. is expected to be a potential market for the growth of this region in the forecast period.
The key players in the human microbiome market are Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), and ViThera Pharmaceuticals (U.S.)
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Human Microbiome Market, By Product
7 Human Microbiome Market, By Application
8 Human Microbiome Market, By Disease
9 Human Microbiome Research Spending Market, By Product
10 Human Microbiome Research Spending Market, By Technology
11 Geographic Analysis
12 Competitive Landscape
13 Company Profiles
14 Appendix
- Du Pont De Nemours and Company
- Enterome Bioscience
- Merck & Co., Inc.
- Metabiomics Corporation
- Microbiome Therapeutics, Llc
- Osel, Inc.
- Second Genome, Inc.
- Vedanta Biosciences, Inc.
- Vithera Pharmaceuticals
- Yakult Honsha Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/q8ggs7/human_microbiome
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Washington Post Publisher Will Lewis Steps Down After Layoffs
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 



